PF-05175157 is a selective inhibitor of both acetyl-CoA carboxylase isoform ACC1 and isoform ACC2 dominant. IC50 values are 27 nM and 33 nM, respectively. It was originated by Pfizer. ACC inihibitors can inhibit de novo lipogenesis and increase β-oxidation of long-chain fatty acids. In Feb 2015, Phase-II for Type-2 diabetes mellitus in USA was discontinued. Source summary: PF 05175157 is a research-use small-molecule compound for biochemical and pharmacology studies; explore its properties and applications.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Endocrinology and Metabolic Disease | ACC
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.